112 related articles for article (PubMed ID: 6141701)
1. Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting.
Agnati LF; Fuxe K; Calza L; Benfenati F; Cavicchioli L; Toffano G; Goldstein M
Acta Physiol Scand; 1983 Dec; 119(4):347-63. PubMed ID: 6141701
[TBL] [Abstract][Full Text] [Related]
2. Further studies on the effects of the GM1 ganglioside on the degenerative and regenerative features of mesostriatal dopamine neurons.
Agnati LF; Fuxe K; Calza L; Goldstein M; Toffano G; Giardino L; Zoli M
Acta Physiol Scand Suppl; 1984; 532():37-44. PubMed ID: 6594030
[TBL] [Abstract][Full Text] [Related]
3. Effect of GM1 ganglioside treatment on the recovery of dopaminergic nigro-striatal neurons after different types of lesion.
Toffano G; Agnati LF; Fuxe K; Aldinio C; Consolazione A; Valenti G; Savoini G
Acta Physiol Scand; 1984 Nov; 122(3):313-21. PubMed ID: 6151339
[TBL] [Abstract][Full Text] [Related]
4. Effects of lesions and ganglioside GM1 treatment on striatal polyamine levels and nigral DA neurons. A role of putrescine in the neurotropic activity of gangliosides.
Agnati LF; Fuxe K; Zini I; Davalli P; Corti A; Calza L; Toffano G; Zoli M; Piccinini G; Goldstein M
Acta Physiol Scand; 1985 Aug; 124(4):499-506. PubMed ID: 2864781
[TBL] [Abstract][Full Text] [Related]
5. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
6. Chronic GM1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat.
Toffano G; Savoini GE; Moroni F; Lombardi G; Calzà L; Agnati LF
Brain Res; 1984 Apr; 296(2):233-9. PubMed ID: 6142756
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with 1-dopa plus carbidopa in hemitransected rats: preferential effects at intact dopamine synapses leading to behavioural signs of dopamine receptor supersensitivity.
Agnati LF; Fuxe K; Calza L; Zini I; Benefenati F; Farabegoli C; Goldstein M
Acta Physiol Scand; 1983 May; 118(1):27-34. PubMed ID: 6137934
[TBL] [Abstract][Full Text] [Related]
8. GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system.
Toffano G; Savoini G; Moroni F; Lombardi G; Calza L; Agnati LF
Brain Res; 1983 Feb; 261(1):163-6. PubMed ID: 6132660
[No Abstract] [Full Text] [Related]
9. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
10. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway.
Ueki A; Rosén L; Andbjer B; Finnman UB; Altamimi U; Janson AM; Goldstein M; Agnati LF; Fuxe K
Exp Brain Res; 1993; 93(2):259-70. PubMed ID: 8098283
[TBL] [Abstract][Full Text] [Related]
11. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection.
Janson AM; Fuxe K; Agnati LF; Kitayama I; Härfstrand A; Andersson K; Goldstein M
Brain Res; 1988 Jul; 455(2):332-45. PubMed ID: 2900058
[TBL] [Abstract][Full Text] [Related]
12. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
Melamed E; Hefti F; Wurtman RJ
Isr J Med Sci; 1982 Jan; 18(1):159-63. PubMed ID: 6121770
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
14. tGS ganglioside induces peculiar morphological features in grafted dopaminergic cells and promotes motor recovery in rats with unilateral lesions in the nigrostriatal dopamine pathway.
Nishino H; Hashitani T; Isobe Y; Furuyama F; Sato H; Kumazaki M; Horikomi K; Awaya A
Brain Res; 1990 Nov; 534(1-2):73-82. PubMed ID: 1981486
[TBL] [Abstract][Full Text] [Related]
15. Chronic nicotine treatment differentially regulates substance P and tyrosine hydroxylase immunoreactivity in substantia nigra ipsilateral to a unilateral lesion.
Janson AM; Fuxe K
Exp Neurol; 1997 Aug; 146(2):575-86. PubMed ID: 9270071
[TBL] [Abstract][Full Text] [Related]
16. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
[TBL] [Abstract][Full Text] [Related]
17. The functional recovery of damaged brain: the effect of GM1 monosialoganglioside.
Toffano G; Savoini G; Aporti F; Calzolari S; Consolazione A; Maura G; Marchi M; Raiteri M; Agnati LF
J Neurosci Res; 1984; 12(2-3):397-408. PubMed ID: 6150119
[TBL] [Abstract][Full Text] [Related]
18. Studies on aging processes.
Agnati LF; Fuxe K; Benfenati F; Toffano G; Cimino M; Battistini N; Calza L; Merlo Pich E
Acta Physiol Scand Suppl; 1984; 532():45-61. PubMed ID: 6093434
[TBL] [Abstract][Full Text] [Related]
19. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
